🏛️ Verified NIH Record • Updated 2026-08-12

ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) (NCT06813664)

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer on Tyrosine Kinase Inhibitor

🟡 Not Yet Recruiting Phase2 📋 Clinical Research Protocol Sponsor: University Health Network, Toronto

🩺 Plain-English Summary (8th-Grade Level)

This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.

Who can join: Review the eligibility criteria below.

Location: Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network — Toronto, Ontario

Age range: 18 Years

🧪 Interventions in This Study

  • Radiotherapy (RADIATION)
  • Radiotherapy (RADIATION)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network — Toronto, Ontario

📞 Contact the Study Coordinator

Phone: (416) 946-4501

Email: jillian.tsai@uhn.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic NSCLC - Non-Small Cell Lung Cancer

Explore by condition: All Metastatic NSCLC - Non-Small Cell Lung Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗